What I am trying to say is that Hepalink ascribed the failure to meet the primary endpoint to the  "lower than anticipated placebo event rate due to the application of new drugs"

I take that to mean (Jardiance) drugs in the SGLT2i class and other drugs which were not in common use when the trial started and which were prescribed after trial start (such as jardiance in my case midway during the trial life)

I tend to relate my health situation to the ongoing trials though I am nowhere sick enough to be considered for one of these trials.